Reference : Recommendations for the reporting harms in manuscripts on clinical trials assessing o...
Scientific journals : Article
Human health sciences : Public health, health care sciences & services
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/235553
Recommendations for the reporting harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
English
Honvo, Germain mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique >]
Bannuru, R.R. [> >]
Bruyère, Olivier mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Rannou, F. [> >]
Herrero-Beaumont, G [> >]
Uebelhart, D. [> >]
Cooper, C. [> >]
Arden, N. [> >]
Conaghan, P.G. [> >]
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Thomas, T. [> >]
McAlindon, T. [> >]
2019
Drugs and Aging
Adis International
36
suppl 1
145-159
Yes (verified by ORBi)
International
1170-229X
1179-1969
United Kingdom
[en] Background : There is strong evidence of under-reporting of harms in manuscripts on randomized controlled trials (RCTs) compared with the volume of raw data retrieved from these trials. Many guidelines have been developed to tackle this, but they have failed to address some important issues that would allow for standardization and transparency. As a consequence, harms reporting in manuscripts remains suboptimal.
Objective: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) aimed to deliver accurate recommendations for better reporting of harms in clinical trials manuscripts on anti-osteoarthritis (OA) drugs. These could help to better inform clinicians on harms recorded in RCTs and further help researchers conducting meta-analyses.
Methods: Using the outcomes of several systematic reviews on the safety of anti-OA drugs, we summarized the ways in which harms have been reported in OA RCT manuscripts to date. Next, we drafted some recommendations and initiated a modified Delphi process that involved a panel of clinicians and clinical researchers to build an expert consensus on recommendations from the ESCEO for the reporting of harms in future manuscripts on RCTs assessing anti-OA drugs.
Results: These recommendations emphasize that all treatment-emergent adverse events (AEs) should always be taken into account for harms reporting, with no frequency threshold, and describe how specific AEs should be reported; they also provide a list of the most relevant organ systems to be considered according to each class of drug for reporting of harms within the results
section of a manuscript. Irrespective of the drug, the ESCEO recommends that total, severe and serious AEs and withdrawals due to AEs should always be reported; guidance on the reporting of specific events pertaining to each category is provided. The ESCEO also recommends the reporting of information on drug effect on biological parameters, with specific guidance. Conclusions These recommendations may contribute to improve transparency in the field of safety of anti-OA edications. Pharmaceutical companies developing drugs for OA, and researchers conducting clinical trials, are encouraged to comply with them when reporting harms-related results in manuscripts on RCTs. The ESCEO also encourages journals to refer to the ESCEO recommendations in their instructions to authors for the publication of manuscripts on trials of anti-OA medications.
http://hdl.handle.net/2268/235553
10.1007/s40266-019-00667-8

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Recommendations for the reporting of harms in manuscripts on clinical trials assessing osteoarthtitis drugs - a consensus statement from the ESCEO.pdfPublisher postprint714.83 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.